Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T05:38:02.382Z Has data issue: false hasContentIssue false
  • English
  • Français

Low-dose neuroleptic therapy and extrapyramidal side effects in schizophrenia: an effect size analysis

Published online by Cambridge University Press:  16 April 2020

C Barbui  and
B Saraceno
C Barbui
Affiliation:
Laboratory of Epidemiology and Social Psychiatry, ‘Mario Negri’ Institute for Pharmacological Research, Via Eritrea 62, 20157Milan, Italy
B Saraceno
Affiliation:
Laboratory of Epidemiology and Social Psychiatry, ‘Mario Negri’ Institute for Pharmacological Research, Via Eritrea 62, 20157Milan, Italy
Get access

Summary

A meta-analysis of the published literature was performed in order to quantify the efficacy of low-dose neuroleptic therapy in reducing extrapyramidal side effects in schizophrenic patients. A low-dose regimen between 50–100 mg equivalents of chlorpromazine, in comparison to a standard-dose regimen between 200–500 mg reduced extrapyramidal side effects by a 0.30 (±0.12) standard deviation, which is only a limited effect.

Keywords

neurolepticlow doseside effects
Type
Short communications
Information
European Psychiatry , Volume 11 , Issue 8 , 1996 , pp. 412 - 415
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baldessarini, RJCohen, BMTeicher, M. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses Arch Gen Psychiatry 1988; 45: 79–91CrossRefGoogle ScholarPubMed
Bangert-Drowns, RL. Review of developments in meta-analytic method Psychol Bull 1986; 99: 388–399CrossRefGoogle Scholar
Barber, JPLuborsky, LBPsychotherapy research: issues to consider in planning a studyHsu, LKJHersen, MResearch in Psychiatry. Issues, Strategies and Methods New York: Plenum, 1992 331–358CrossRefGoogle Scholar
Barbui, C. Terapia a lungo termine delle psicosi: neurolettici ed interventi psicosociali Lett Perc Bibliogr Psichiat 1995 XIX 1–36Google Scholar
Barbui C, Saraceno B, Liberati A, Garattini S. Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials. Eur Psychiatry (in press)Google Scholar
Bollini, PPampallano, SOrza, MJAdams, MEChalmers, TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized controlled trials Psychol med 1994; 24: 307–316CrossRefGoogle Scholar
Burnett, PLGalletly, CAMoyle, RClark, CR. Low-dose depot medication in schizophrenia Schizophren Bull 19 1993 155–164CrossRefGoogle Scholar
Cohen, J2nd edn Statistical Power Analysis for the Social Sciences New York: Academic Press, 1977Google Scholar
Gilbert, PLHarris, MJMcAdams, LAJeste, DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature Arch Gen Psychiatry 1995; 52: 173–188CrossRefGoogle ScholarPubMed
Hasselblad, VMosteller, FLittenberg, B, et al.A survey of current problems in meta-analysis Med Care 1995; 33: 202–220CrossRefGoogle ScholarPubMed
Hogarty, GEMcEvoy, JPMunetz, M, et al.Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia Arch Gen Psychiatry 1988; 45: 797–805CrossRefGoogle Scholar
Inderbitzin, LBLewine, RRJScheller-Gilkey, Get al.A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients Am J Psychiatry 1994; 151: 1753–1759Google ScholarPubMed
Johnson, DAWLudlow, JMStreet, KTaylor, RDW. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia Br J Psychiatry 1987; 151: 634–638CrossRefGoogle Scholar
Kane, JMRifkin, AWoerner, MReardon, GSarantakos, SSchiebel, DRamos-Lorenzi, J. Low-dose neuroleptic treatment of outpatient schizophrenics Arch Gen Psychiatry 1983; 40: 893–896CrossRefGoogle ScholarPubMed
Marder, SRVan, Putten TMintz, J, et al.Costs and benefits of two doses of fluphenazine Arch Gen Psychiatry 1984; 41: 1025–1029CrossRefGoogle ScholarPubMed
Marder, SRVan, Putten TMintz, JLebell, MMcKenzie, JMay, PRA. Low-and conventional-dose maintenance therapy with fluphenazine decanoate Arch Gen Psychiatry 1987; 44: 518–521CrossRefGoogle ScholarPubMed
Morgenstern, HGlazer, WMNiedzwiecki, DNourjah, P. The impact of neuroleptic medication on tardive diskinesia: a meta-analysis of published studies Am J Publ Health 1987; 77: 717–724CrossRefGoogle Scholar
Rosenthal, RRubin, DB. Comparing effect sizes of independent studies Psychol Bull 1982; 92: 500–504CrossRefGoogle Scholar
Saraceno, B. Los psicofármacos en una perspectiva de salud pública Acta Psiquiát Psicol Am Lat 1993; 40: 63–68Google Scholar
Schooler, NR. Maintenance medication for schizophrenia: strategies for dose reduction Schizophren Bull 1991; 17: 311–324CrossRefGoogle ScholarPubMed
Schooler, NR. Reducing dosage in maintenance treatment of schizophrenia Br J Psychiatry 1993 163suppl 22 58–65CrossRefGoogle Scholar
Streiner, DL. Using meta-analysis in psychiatric research Can J Psychiatry 1991; 36: 357–362CrossRefGoogle ScholarPubMed
Thacker, SB. Meta-analysis. A quantitative approach to research integration 7 Am Med Assoc 1988; 259: 1685–1689CrossRefGoogle Scholar
Wyatt, R. Neuroleptics and the natural course of schizophrenia Schizophren Bull 1991; 17: 325–351CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.